Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations
Standard
Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations. / Jost, Wolfgang H; Bäumer, Tobias; Bevot, Andrea; Birkmann, Ulrich; Buhmann, Carsten; Grosheva, Maria; Guntinas-Lichius, Orlando; Laskawi, Rainer; Paus, Sebastian; Pflug, Christina; Schroeder, A Sebastian; Spittau, Björn; Steffen, Armin; Wilken, Bernd; Winterholler, Martin; Berweck, Steffen.
in: FRONT NEUROL, Jahrgang 14, 2023, S. 1275807.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations
AU - Jost, Wolfgang H
AU - Bäumer, Tobias
AU - Bevot, Andrea
AU - Birkmann, Ulrich
AU - Buhmann, Carsten
AU - Grosheva, Maria
AU - Guntinas-Lichius, Orlando
AU - Laskawi, Rainer
AU - Paus, Sebastian
AU - Pflug, Christina
AU - Schroeder, A Sebastian
AU - Spittau, Björn
AU - Steffen, Armin
AU - Wilken, Bernd
AU - Winterholler, Martin
AU - Berweck, Steffen
N1 - Copyright © 2023 Jost, Bäumer, Bevot, Birkmann, Buhmann, Grosheva, Guntinas-Lichius, Laskawi, Paus, Pflug, Schroeder, Spittau, Steffen, Wilken, Winterholler and Berweck.
PY - 2023
Y1 - 2023
N2 - Sialorrhea is defined as a chronic excessive flow of saliva from the mouth, often with adverse consequences for health and quality of life of patients. In addition to currently used non-drug treatment and systemic drugs, intraglandular Botulinum Neurotoxin A (BoNT/A) injections have been examined in case studies, controlled trials and clinical practice. Two pivotal Phase III trials recently led to market approval in the USA and EU for IncobotulinumtoxinA [Xeomin®, IncoBoNT/A, Clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins, Merz Pharmaceuticals GmbH] for treatment of chronic sialorrhea in adults and pediatric patients. This review provides a multidisciplinary approach to discuss the current state of sialorrhea therapy as well as benefits and current limitations of BoNT/A injections. A consensus regarding treatment recommendations made available to physicians in Germany in 2022 has now been updated here for presentation to an international audience. This review provides a framework including a flow chart for patient selection, recommendations for dosing and the injection process, as well as a discussion of therapeutic goals, long-term benefits and safety aspects. This review is aimed at supporting physicians in developing multidisciplinary and individualized treatment approaches to achieve optimal benefits for patients.
AB - Sialorrhea is defined as a chronic excessive flow of saliva from the mouth, often with adverse consequences for health and quality of life of patients. In addition to currently used non-drug treatment and systemic drugs, intraglandular Botulinum Neurotoxin A (BoNT/A) injections have been examined in case studies, controlled trials and clinical practice. Two pivotal Phase III trials recently led to market approval in the USA and EU for IncobotulinumtoxinA [Xeomin®, IncoBoNT/A, Clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins, Merz Pharmaceuticals GmbH] for treatment of chronic sialorrhea in adults and pediatric patients. This review provides a multidisciplinary approach to discuss the current state of sialorrhea therapy as well as benefits and current limitations of BoNT/A injections. A consensus regarding treatment recommendations made available to physicians in Germany in 2022 has now been updated here for presentation to an international audience. This review provides a framework including a flow chart for patient selection, recommendations for dosing and the injection process, as well as a discussion of therapeutic goals, long-term benefits and safety aspects. This review is aimed at supporting physicians in developing multidisciplinary and individualized treatment approaches to achieve optimal benefits for patients.
U2 - 10.3389/fneur.2023.1275807
DO - 10.3389/fneur.2023.1275807
M3 - SCORING: Review article
C2 - 38162447
VL - 14
SP - 1275807
JO - FRONT NEUROL
JF - FRONT NEUROL
SN - 1664-2295
ER -
